SCHEMBL31371069

SCHEMBL31371069

C=Cc1ccc(OC(F)(F)CO)cn1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.30
▸ CYP4F2 P78329 1/20 0.30
▸ CYP4A11 Q02928 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31371172 0.84 ALDH1A1 (0.32) —
SCHEMBL16248103 0.81 ABL1 (0.38) —
SCHEMBL31370973 0.76 CHRNB2 (0.35) —
SCHEMBL24244752 0.75 TUBB4A (0.34) —
SCHEMBL16248094 0.72 PPARA (0.55) —
SCHEMBL16248104 0.70 SRD5A1 (0.33) —
SCHEMBL16248105 0.70 MCHR1 (0.36) —
SCHEMBL31362938 0.69 — —
SCHEMBL18951811 0.69 TUBB4A (0.51) —
SCHEMBL34470800 0.68 DRD1 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038782-A1 ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE LUCY THERAPEUTICS, INC. (US) 2025-02-20 — — WO disclosed
Send feedback